Quick Answer
A randomized clinical trial found that Pediococcus acidilactici PA53 was associated with improved happiness, sleep quality and digestive symptoms in adults aged 55 to 70. The eight-week study measured changes in 69 participants who completed the trial, while the researchers described the findings as promising but preliminary.
What Did the PA53 Trial Find?
The double-blind, placebo-controlled trial enrolled 75 healthy older adults. One group received a daily dose of 30 billion colony-forming units of Pediococcus acidilactici PA53, while the other received a placebo.
Among the 69 participants who completed the study, those assigned PA53 had a 12.7% increase in happiness scores from baseline. Sleep quality, measured with the Pittsburgh Sleep Quality Index, improved by 23%.
Digestive symptom scores declined 9.5%, and stool consistency improved by 28% on the Bristol Stool Scale. The probiotic group also had significantly better stress-score results than the placebo group, although the 3.3% reduction in stress scores within the probiotic group was not statistically significant on its own.
What Changed in Inflammation and Gut Bacteria?
Blood tests found significant decreases in the inflammation markers IL-6 and TNF-? in the PA53 group. Levels of IL-25, a cytokine involved in intestinal repair and immune balance, rose notably.
Microbiome analysis showed changes in several bacterial genera after PA53 supplementation. Ruminococcus doubled in abundance, Blautia increased from 7.6% to 11.4%, and Faecalibacterium rose from 6.9% to 10.6%.
How Should the Findings Be Interpreted?
Fei Xu described the study as early clinical evidence supporting PA53 in older adults but not the final word. The study included 75 people, lasted eight weeks and ended with 69 completers.
Fei Xu, the corresponding author of the study, said previous preclinical work had assessed the strain’s safety and its ability to survive stomach acid and bile before human trials. Xu also noted that not every psychological measure improved by a statistically significant amount.
According to Xu, larger and longer-term studies are needed to confirm the durability and generalizability of the results. The trial was published in The Journal of Nutrition.
What Does the Broader Microbiome Research Show?
Research on probiotics and the gut microbiome describes several mechanisms through which dietary nutrients and live microorganisms can affect intestinal microbial communities. A 2024 review in the International Journal of Molecular Sciences describes how gut microbes convert dietary nutrients into metabolites that can affect immune regulation and describes probiotics as potentially influencing the abundance and function of intestinal bacteria.

A separate 2013 review in Therapeutic Advances in Gastroenterology covers the proposed roles of probiotics in changing gut microbiota composition and function, including immune and neurological effects. That review also discusses dietary nutrients and microbial conversion within the intestine as influences on microbial communities.
A 2026 review in Frontiers in Microbiomes notes that diet, age, genetics, lifestyle and environment can affect gut microbiota diversity and composition. It also cautions that taxonomic profiling, observational designs, inter-individual variation and methodological differences limit reproducibility and causal inference in microbiome research.
Probiotics for Insomnia Review and Probiotics and Anxiety Meta-Analysis
The 2025 Probiotics for Insomnia Review included six studies encompassing 424 patients with insomnia. Probiotic interventions were associated with a significant reduction in Pittsburgh Sleep Quality Index scores, with a mean difference of, 2.10 and 95% confidence interval of, 3.86 to, 0.34. Hamilton Depression Scale scores also showed a significant reduction, with a mean difference of, 7.72 and 95% confidence interval of, 14.55 to, 0.89, although the evidence had very low certainty. No significant differences in total adverse events were noted between probiotic and control groups. The authors said further high-quality clinical studies were warranted because of the limited sample size.

The 2018 Probiotics and Anxiety Meta-Analysis extracted data from 22 preclinical studies covering 743 animals and 14 clinical studies covering 1,527 individuals. Probiotics reduced anxiety-like behavior in animals in the pooled analysis. Subgroup analyses revealed a significant reduction only among diseased animals. Probiotics did not significantly reduce symptoms of anxiety in humans and did not differentially affect clinical and healthy human samples. The authors said the animal findings had not yet translated to clinical research in humans.
What Should Readers Check Before Buying?
PA53 is identified by its full strain name, Pediococcus acidilactici PA53. Dietitians cited in the report recommend checking the strain designation on a probiotic label because benefits from one strain do not automatically apply to another.
The strain was developed and sold by China’s Wecare Probiotics, which supplied both the trial product and placebo. According to Xu, the company did not fund the study or control its data.
The report also notes that the bacteria that increased during the trial feed on fiber. It identifies vegetables, beans and whole grains as fiber-containing foods that can support those bacteria. As with any new supplement, readers are advised to check with a healthcare provider before starting.
What the Evidence Shows
- The PA53 trial included 75 healthy adults aged 55 to 70, with 69 completers after eight weeks.
- The probiotic group received 30 billion CFUs of Pediococcus acidilactici PA53 daily.
- Happiness scores increased 12.7%, sleep quality improved 23%, digestive symptom scores fell 9.5%, and stool consistency improved 28% on the Bristol Stool Scale.
- Stress scores within the probiotic group declined 3.3%, which was not statistically significant on its own, although the group performed significantly better than placebo.
- IL-6 and TNF-? decreased significantly, while Ruminococcus, Blautia and Faecalibacterium increased in the microbiome analysis.
Key Considerations
- The trial was relatively small and lasted eight weeks.
- Not every psychological measure showed a statistically significant improvement.
- The researchers said larger and longer-term studies are needed.
- The trial studied one specified strain, so benefits cannot automatically be transferred to other probiotic strains.
- The strain was supplied by Wecare Probiotics, although Xu said the company did not fund the study or control its data.
What to Do Now
- Check the full probiotic strain name on the label.
- Compare the strain with the one studied, Pediococcus acidilactici PA53.
- Review the trial duration and outcome measures with a healthcare provider.
- Ask a healthcare provider about starting a new supplement.
- Include fiber-containing foods such as vegetables, beans and whole grains in your regular meals.
FAQ
What Probiotic Strain Was Studied for Sleep and Mood in Older Adults?
The trial studied Pediococcus acidilactici PA53, given at 30 billion CFUs daily for eight weeks.
How Did PA53 Affect Sleep Quality in the Trial?
Sleep quality, measured with the Pittsburgh Sleep Quality Index, improved by 23% among participants who completed the trial.
Did the Probiotic Improve Happiness and Digestion?
Happiness scores increased 12.7%, digestive symptom scores fell 9.5%, and stool consistency improved 28% on the Bristol Stool Scale.
Did PA53 Improve Stress Levels?
Stress scores declined 3.3% within the probiotic group, but that change was not statistically significant on its own. The probiotic group performed significantly better than the placebo group.
Is Pediococcus Acidilactici PA53 Widely Available?
The report says PA53 is not easy to find on store shelves. The strain is developed and sold by China’s Wecare Probiotics, which supplied the product and placebo used in the trial.
Related Coverage
- Low Vitamin D Linked to Mood, PMOS Symptoms, and Sleep Apnea in Women (October 22, 2026): A report published Aug., RDN.
- Blood Sleep Signature Linked to Lower Digestive Cancer Risk (November 9, 2026): com, a blood “sleep signature” was linked to up to 71% lower risk of some digestive cancers and was reported at Digestive Disease Week 2026.
- Citicoline Supplement Linked to Memory Gains in Healthy Older Adults, Study Finds
